Rhumbline Advisers Buys 1,765 Shares of Amedisys Inc (AMED)
Rhumbline Advisers grew its stake in shares of Amedisys Inc (NASDAQ:AMED) by 3.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 55,951 shares of the health services provider’s stock after purchasing an additional 1,765 shares during the quarter. Rhumbline Advisers owned 0.17% of Amedisys worth $3,131,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Riverhead Capital Management LLC increased its position in shares of Amedisys by 75.5% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after acquiring an additional 831 shares during the last quarter. Federated Investors Inc. PA increased its position in shares of Amedisys by 2.3% during the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after acquiring an additional 44 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in shares of Amedisys during the third quarter worth about $205,000. CIBC Asset Management Inc purchased a new stake in shares of Amedisys during the second quarter worth about $230,000. Finally, SG Americas Securities LLC increased its position in shares of Amedisys by 48.7% during the second quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock worth $235,000 after acquiring an additional 1,226 shares during the last quarter. Institutional investors own 94.32% of the company’s stock.
Amedisys Inc (NASDAQ AMED) opened at $53.85 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16. Amedisys Inc has a 52 week low of $39.95 and a 52 week high of $65.91. The company has a market capitalization of $1,797.29, a P/E ratio of 25.34, a price-to-earnings-growth ratio of 1.28 and a beta of 0.70.
Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The company had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. During the same period in the previous year, the firm posted $0.36 earnings per share. Amedisys’s quarterly revenue was up 5.1% compared to the same quarter last year. equities research analysts predict that Amedisys Inc will post 2.23 EPS for the current year.
A number of brokerages have recently issued reports on AMED. BidaskClub raised Amedisys from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Robert W. Baird reissued a “hold” rating and issued a $50.00 price objective on shares of Amedisys in a report on Wednesday, October 4th. Mizuho reissued a “buy” rating and issued a $65.00 price objective (up from $55.00) on shares of Amedisys in a report on Wednesday, November 8th. Benchmark reissued a “hold” rating on shares of Amedisys in a report on Thursday, November 9th. Finally, Bank of America began coverage on Amedisys in a report on Monday, August 21st. They issued a “neutral” rating and a $55.00 price objective for the company. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Amedisys has a consensus rating of “Buy” and an average price target of $61.00.
ILLEGAL ACTIVITY NOTICE: “Rhumbline Advisers Buys 1,765 Shares of Amedisys Inc (AMED)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/09/rhumbline-advisers-buys-1765-shares-of-amedisys-inc-amed.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.